A. Shustov

发表

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

C. Elmets, J. Scarisbrick, P. Zinzani, 2018, The Lancet. Oncology.

Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

B. Coiffier, S. Horwitz, H. Prince, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.

S. Pergam, R. Lynch, M. Shadman, 2020, JCO oncology practice.

Emerging Immunotherapy Approaches in Peripheral T‐cell Lymphomas

B. Pro, A. Shustov, 2021 .

Kikuchi-Fujimoto Disease Associated With Subcutaneous Panniculitis-Like T-Cell Lymphoma.

M. Shinohara, A. Shustov, Xueyan Chen, 2016, The American Journal of dermatopathology.

Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials

B. Coiffier, S. Bates, S. Horwitz, 2017, Leukemia & lymphoma.

Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

S. Horwitz, O. O’Connor, Helen Ma, 2020, Leukemia and Lymphoma.

Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, D. Maloney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Novel therapies for peripheral T-cell lymphomas

A. Shustov, 2013, Therapeutic advances in hematology.

Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.

J. Fromm, A. Gopal, A. Shustov, 2012, Clinical lymphoma, myeloma & leukemia.

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

K. Savage, F. Morschhauser, L. Trümper, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

E. Warren, R. Lynch, M. Shadman, 2021, The Lancet. Haematology.

Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.

S. Montoto, S. Pileri, M. Federico, 2020, The Lancet. Haematology.

Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study.

M. Federico, C. Gisselbrecht, S. Horwitz, 2020, Clinical lymphoma, myeloma & leukemia.

Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study.

G. Bhagat, Craig R Soderquist, C. Deng, 2020, Blood.

ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY.

G. Bhagat, Craig R Soderquist, C. Deng, 2019, Blood.

A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks

T. Gooley, J. Fromm, E. Libby, 2018, British journal of haematology.

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

R. Advani, Sonali M. Smith, A. Tulpule, 2019, Cancer.

Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial

David Wu, T. Gooley, O. Press, 2018, British journal of haematology.

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

R. Advani, S. Horwitz, T. Illidge, 2018, Blood.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

J. Burke, J. Essell, Robert Chen, 2018, Clinical lymphoma, myeloma & leukemia.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

R. Advani, J. Connors, T. Illidge, 2017, Blood.

Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting

J. Connors, A. Younes, A. Engert, 2016, Clinical trials.

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

S. Smith, D. Maloney, J. Pagel, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

High‐dose CD20‐targeted radioimmunotherapy‐based autologous transplantation improves outcomes for persistent mantle cell lymphoma

D. Maloney, J. Pagel, J. Rajendran, 2015, British journal of haematology.

Brentuximab vedotin administered to platinum‐refractory, transplant‐naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status

D. Maloney, J. Pagel, O. Press, 2015, Hematological oncology.

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

R. Advani, S. Horwitz, T. Illidge, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

D. Fisher, S. Horwitz, N. Bartlett, 2012, Blood.

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction of CTL Humoral Autoimmunity by Preventing the Promotes α In Vivo Neutralization of TNF-

V. Rus, P. Nguyen, A. Shustov, 2001 .

In Vivo Neutralization of TNF-α Promotes Humoral Autoimmunity by Preventing the Induction of CTL1

F. Finkelman, V. Rus, P. Nguyen, 2001, The Journal of Immunology.

NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.

M. Dwyer, A. Goodman, S. Ansell, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.

M. Dwyer, S. Ansell, Hema M Sundar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium

J. Pagel, T. Gooley, S. Petersdorf, 2010, Leukemia & lymphoma.

A 60-year-old Indian male with altered sensorium and extensive lymphoma of the scalp.

M. Chamberlain, H. Newton, B. Yadav, 2013, Seminars in oncology.

A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma

J. Pagel, T. Gooley, O. Press, 2013, British journal of haematology.

Fas Expression on Antigen-Specific T Cells Has Costimulatory, Helper, and Down-Regulatory Functions In Vivo for Cytotoxic T Cell Responses but Not for T Cell-Dependent B Cell Responses1

M. Haas, A. Shustov, C. Via, 2008, The Journal of Immunology.

A major role for the Fas pathway in acute graft-versus-host disease.

K. Elkon, P. Nguyen, J. Drappa, 1996, Journal of immunology.

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2014 .

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.

B. Coiffier, C. Haioun, S. Horwitz, 2012, Clinical lymphoma, myeloma & leukemia.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

R. Advani, Sonali M. Smith, A. Tulpule, 2019, Acta Haematologica.

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

B. Coiffier, S. Horwitz, H. Prince, 2014, Journal of Hematology & Oncology.

Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.

K. Savage, P. Zinzani, S. Horwitz, 2013 .

Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.

F. Finkelman, K. Elkon, P. Nguyen, 1998, Journal of immunology.

Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity.

K. Elkon, J. Papadimitriou, I. Luzina, 2000, The Journal of clinical investigation.

Eligibility for CAR T‐cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL

E. Warren, R. Lynch, C. Ujjani, 2019, American journal of hematology.

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma

B. Coiffier, S. Horwitz, H. Prince, 2016, Hematological oncology.

Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity

D. Maloney, B. Storer, J. Pagel, 2015, Leukemia & lymphoma.

Utility of 18 ﬂ uoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

er, F. Morschhauser, S. Horwitz, 2015 .

Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas

R. Advani, S. Horwitz, T. Illidge, 2013 .

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2013 .

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.

R. Advani, Y. Oki, S. Horwitz, 2012 .

Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy

D. Maloney, E. Warren, C. Turtle, 2019, American journal of hematology.

How I treat primary cutaneous CD30+ lymphoproliferative disorders.

M. Shinohara, A. Shustov, 2019, Blood.

Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma

B. Coiffier, S. Horwitz, H. Prince, 2011 .

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

R. Advani, J. Connors, T. Illidge, 2011 .

Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm

E. Estey, M. Othus, R. Walter, 2019, Leukemia.

Pegylated GCSF Can Be Used With First‐Line da‐EPOCH‐R Without Compromising Dose Intensity, Safety, or Efficacy

O. Press, R. Cassaday, A. Cowan, 2017, Clinical lymphoma, myeloma & leukemia.

NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.

M. Dwyer, A. Goodman, S. Ansell, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Pralatrexate for refractory or recurrent subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome.

M. Shinohara, A. Shustov, Olivia R. Ware, 2020, Journal of the American Academy of Dermatology.

Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.

A. Shustov, 2013, Best practice & research. Clinical haematology.

Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia

E. Estey, B. Storer, D. Stirewalt, 2011, British journal of haematology.

Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.

E. Estey, B. Storer, D. Stirewalt, 2010 .

T Cell Activation and IFN-+ Requires CD 8 Disease : Up-Regulation of Fas and Fas Ligand in Acute and Chronic Graft-Versus-Host Differential Expression of Fas and Fas Ligand Elkon and

F. Finkelman, K. Elkon, P. Nguyen, 1998 .

Phase II study of idelalisib, a selective inhibitor of PI3K d , for relapsed/refractory classical Hodgkin lymphoma

A. Younes, M. Fanale, C. Moskowitz, 2017 .

A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States

R. Advani, Sonali M. Smith, A. Tulpule, 2017, Cancer.

Murine Graft-vs-Host Disease

P. Nguyen, A. Shustov, C. Via, 1999 .

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2016 .

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

K. Savage, P. Zinzani, S. Horwitz, 2014 .

Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL).

L. Hughey, P. Zinzani, T. Kuzel, 2014 .

belinostat In Relapsed Or Refractory Peripheral T-cell Lymphoma (r/r Ptcl) Subtype Angioimmunoblastic T-cell Lymphoma (aitl): Results From The Pivotal Belief Trial : 153

P. Zinzani, S. Horwitz, O. O’Connor, 2013 .

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2010 .

Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy

B. Coiffier, S. Horwitz, H. Prince, 2010 .

A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial

J. Vose, Sonali M. Smith, K. Savage, 2013 .

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas

R. Advani, S. Horwitz, T. Illidge, 2012 .

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

R. Advani, S. Montoto, M. Federico, 2018, Haematologica.

Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas

D. Maloney, David Wu, O. Press, 2016, Bone Marrow Transplantation.

Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T‐cell and natural killer‐cell lymphomas

M. Sorror, R. Storb, B. Sandmaier, 2010, British journal of haematology.

T-cell lymphoma – one name with a dozen faces

A. Shustov, 2008, Leukemia & lymphoma.

Does high-dose therapy and autologous hematopoietic stem cell transplantation have a role in the primary treatment of peripheral T-cell lymphomas? ASH evidence-based review 2008.

K. Savage, A. Shustov, 2008, Hematology. American Society of Hematology. Education Program.

Evidence-based guidelines--an introduction.

V. Bachanova, M. Crowther, R. Rosovsky, 2008, Hematology. American Society of Hematology. Education Program.

Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry

M. Federico, C. Gisselbrecht, S. Horwitz, 2019, American journal of hematology.

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.

O. Akilov, C. Querfeld, John A Thompson, 2021, The Lancet. Haematology.

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

J. Leonard, F. d'Amore, K. Venkatakrishnan, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T-Cell Acute Lymphoblastic Leukemia

F. Appelbaum, A. Shustov, 2011 .

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

K. Savage, B. Coiffier, C. Gisselbrecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Risk Stratification and Strategies

A. Shustov, 2012 .

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

K. Savage, S. Horwitz, L. F. Allen, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Roland Schmitz, Chih-Jian Lih, L. Staudt, 2015, Nature Medicine.

Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway

K. Kolibaba, F. Awan, Mitchell R. Smith, 2016 .

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

L. Staudt, W. Wilson, R. Advani, 2012 .

Phase II study of idelalisib, a selective inhibitor of PI3K&dgr;, for relapsed/refractory classical Hodgkin lymphoma

A. Younes, S. Mitra, M. Fanale, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Matthew Greenwood, Martin Wilhelm, B. Coiffier, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T/NK-cell Lymphomas: A Histology-Specific Review.

A. Shustov, Tejaswini M Dhawale, 2017, Hematology/oncology clinics of North America.

Central nervous system involvement in cutaneous T-cell lymphoma: 2 illustrative cases and a review of current literature.

J. Olerud, M. Chamberlain, M. Shinohara, 2014, Clinical lymphoma, myeloma & leukemia.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

R. Advani, J. Connors, T. Illidge, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Peripheral T cell lymphoma , not otherwise specified ( PTCL-NOS ) . A new prognostic model developed by the International T cell Project Network

R. Advani, J. Vose, S. Montoto, 2022 .

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.

D. Maloney, David Wu, O. Press, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL.

F. Finkelman, P. Nguyen, A. Shustov, 2001, Journal of immunology.

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

R. Korn, G. Shapiro, F. Meric-Bernstam, 2018, Blood.

Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy

R. Lynch, M. Shadman, R. Cassaday, 2020, British journal of haematology.

T‐Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

J. Friedberg, J. Leonard, S. Horwitz, 2017, Journal of the National Cancer Institute.

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

H. Kohrt, R. Pierce, H. Maecker, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.

P. Newcomb, S. Adams, A. Shustov, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).

U. Jaeger, M. Mayerhoefer, T. Kadia, 2019, Blood.

In‐vivo purging of the circulating clonal T‐cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation

D. Maloney, A. Gopal, A. Shustov, 2011, British journal of haematology.

ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.

J. Vose, J. Radford, M. Federico, 2021, Blood advances.

Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) — Results from a Prospective Multicenter Phase 2 Clinical Trial

S. Dakhil, M. Shinohara, J. Zain, 2018, Blood.

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Y. Oki, S. Barta, A. Shustov, 2017 .

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

H. Deeg, D. Maloney, E. Warren, 2019, Clinical lymphoma, myeloma & leukemia.

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

A. LaCasce, J. Friedberg, I. Flinn, 2016, European journal of cancer.

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

J. Drachman, R. Furman, A. Forero-Torres, 2010, Leukemia & lymphoma.

Leukemic phase of primary cutaneous anaplastic large-cell lymphoma (ALK-negative), with downregulation of CD30

A. Shustov, L. Soma, C. Murphy, 2018, Journal of Hematopathology.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

M. Liedtke, H. Kantarjian, W. Stock, 2017, Blood advances.

Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia

E. Estey, R. Walter, P. Becker, 2021, Cancer.

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

D. Maloney, E. Warren, C. Turtle, 2018, Blood.

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

H. Kohrt, H. Maecker, J. Yearley, 2018, Blood.

Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.

A. Shustov, L. Soma, 2018, Cancer treatment and research.

Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission

D. Maloney, J. Pagel, O. Press, 2016, Leukemia & lymphoma.

Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD

B. Wood, B. Sandmaier, P. Becker, 2018, American journal of hematology.

Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia

M. Bar, B. Wood, M. Sorror, 2016, Leukemia & lymphoma.

Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)

R. Advani, Sonali M. Smith, A. Tulpule, 2014 .

Extranodal natural killer T-cell lymphoma-new profiling, old tricks.

A. Shustov, 2016, The Lancet. Oncology.

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial

R. Advani, Sonali M. Smith, K. Savage, 2016, British journal of haematology.

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Scott E. Smith, J. Friedberg, A. Younes, 2014, Leukemia & lymphoma.

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

Ash A. Alizadeh, H. Kohrt, H. Maecker, 2016 .

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

K. Savage, P. Zinzani, S. Horwitz, 2022, Blood advances.

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

R. Advani, K. Savage, Y. Oki, 2017, Leukemia & lymphoma.

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia

E. Estey, J. Radich, R. Walter, 2023, Leukemia & lymphoma.

Analysis of Peripheral T‐cell Lymphoma Diagnostic Workup in the United States

R. Advani, Sonali M. Smith, A. Tulpule, 2017, Clinical lymphoma, myeloma & leukemia.

Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).

B. Coiffier, S. Horwitz, H. Prince, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

C. Gisselbrecht, S. Horwitz, N. Bartlett, 2010 .

Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project.

R. Advani, J. Vose, S. Montoto, 2021, Blood.

A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage

H. Kantarjian, W. Stock, D. DeAngelo, 2014 .

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL): Initial Results of a Phase II Trial

E. Estey, J. Radich, P. Becker, 2018, Blood.

PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma

K. Savage, B. Coiffier, P. Zinzani, 2008 .

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma

R. Advani, R. Bouabdallah, H. Tilly, 2015, Leukemia & lymphoma.

Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression

R. Lynch, M. Shadman, R. Cassaday, 2020 .

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.

R. Advani, J. Vose, S. Montoto, 2021, Blood.

Subsequent Hematopoietic Stem Cell Transplantation in Belinostat-Treated Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

S. Horwitz, L. F. Allen, O. Visser, 2014 .

Efficacy of Short-Duration Alemtuzumab in T-Cell Large Granular Lymphocytic Leukemia: Potential for a Response-Adapted Strategy

A. Gopal, A. Shustov, I. Huang, 2022, Blood.

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

R. Advani, K. Savage, S. Horwitz, 2021, Blood.

Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival.

S. Horwitz, E. Jacobsen, O. O’Connor, 2010 .

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant

R. Advani, K. Savage, P. Zinzani, 2019, Blood.

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

D. Fisher, S. Horwitz, N. Bartlett, 2010 .

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

R. Advani, K. Savage, P. Zinzani, 2020 .

PEMBROLIZUMAB WITH RCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL AND GRADE 3B FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I TRIAL

R. Lynch, R. Cassaday, A. Cowan, 2019, Hematological Oncology.

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

K. Savage, B. Coiffier, S. Horwitz, 2010 .

Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.

R. Advani, Y. Oki, N. Bartlett, 2012 .

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

J. Drachman, R. Furman, A. Forero-Torres, 2010, Leukemia & lymphoma.

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

R. Advani, S. Montoto, M. Federico, 2018, Haematologica.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

C. Elmets, J. Scarisbrick, P. Zinzani, 2018, The Lancet. Oncology.

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

E. Estey, B. Storer, F. Appelbaum, 2008 .

Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.

D. Maloney, J. Pagel, K. Guthrie, 2012 .

A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.

J. Pagel, T. Gooley, A. Gopal, 2009 .

In‐vivo purging of the circulating clonal T‐cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation

D. Maloney, A. Gopal, A. Shustov, 2011, British journal of haematology.

Evidence-based guidelines--an introduction.

V. Bachanova, M. Crowther, R. Rosovsky, 2008, Hematology. American Society of Hematology. Education Program.

Cutaneous manifestations of angioimmunoblastic T-cell lymphoma.

M. Shinohara, A. Shustov, K. White, 2019, Dermatology online journal.

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

R. Advani, J. Connors, T. Illidge, 2012 .